<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20210825105100Z</creation_date><modification_date>D:20221117105100Z</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-3-22-2689_o_dec_1.pdf</pdf_file></head><body><section><header>enen</header><p>european commission
 brussels, 10.8.2022c(2022)5919 (final) corr</p></section><section><header>commission implementing decisionof 10.8.2022
 relating to the designation of &quot;(7s)-8,8-dimethyl-7-{[(2e)-3-phenyl-2-propen-1-yl]oxy}-
 7,8-dihydro-2h,6h-pyrano[3,2-g]chromen-2-one&quot; as an orphan medicinal product 
 under regulation (ec) no 141/2000 of the european parliament and of the council</header><p>(text with eea relevance) (only the polish text is authentic)</p></section><section><header>en</header><p>1</p></section><section><header>en</header></section><section><header>commission implementing decisionof 10.8.2022
 relating to the designation of &quot;(7s)-8,8-dimethyl-7-{[(2e)-3-phenyl-2-propen-1-yl]oxy}-
 7,8-dihydro-2h,6h-pyrano[3,2-g]chromen-2-one&quot; as an orphan medicinal product 
 under regulation (ec) no 141/2000 of the european parliament and of the council</header><p>(text with eea relevance)(only the polish text is authentic)
 the european commission,
 having regard to the treaty on the functioning of the european union,
 having regard to regulation (ec) no 141/2000 of the european parliament and of the 
 council of 16 december 1999 on orphan medicinal products
 1, and in particular the first sentence of article 5(8) thereof,
 having regard to the application submitted by global medical services sp. z o.o. on 18 may 
 2022 under article 5(1) of regulation (ec) no 141/2000,
 having regard to the favourable opinion of the european medicines agency, drawn up on 14 
 july 2022 by the committee for orphan medicinal products and received by the commission 
 on 22 july 2022,
 whereas:
 (1)
 the application submitted by global medical services sp. z o.o. concerning the 
 medicinal 
 product 
 “(7s)-8,8-dimethyl-7-{[(2e)-3-phenyl-2-propen-1-yl]oxy}-7,8-
 dihydro-2h,6h-pyrano[3,2-g]chromen-2-one” was validated on 14 june 2022 under 
 article 5(4) of regulation (ec) no 141/2000.
 (2)
 &quot;(7s)-8,8-dimethyl-7-{[(2e)-3-phenyl-2-propen-1-yl]oxy}-7,8-dihydro-2h,6h-
 pyrano[3,2-g]chromen-2-one&quot; meets the designation criteria referred to in article 3(1) 
 of regulation (ec) no 141/2000.
 (3)
 the application should therefore be accepted,
 has adopted this decision:
 article 1the medicinal 
 product 
 “(7s)-8,8-dimethyl-7-{[(2e)-3-phenyl-2-propen-1-yl]oxy}-7,8-
 dihydro-2h,6h-pyrano[3,2-g]chromen-2-one” is designated as an orphan medicinal product 
 for the indication: treatment of hutchinson-gilford progeria syndrome. it shall be entered in 
 the community register of orphan medicinal products under number eu/3/22/2689.
 1oj l 18, 22.1.2000, p.1.</p></section><section><header>en</header><p>2</p></section><section><header>en</header><p>article 2the european medicines agency shall make available to all interested parties the opinion of the committee on orphan medicinal products referred to in this decision.
 article 3this decision is addressed to global medical services sp. z o.o., ul. berezynska 39/38 39, 03-908 warsaw, mazowieckie, polska.
 done at brussels, 10.8.2022
 for the commissionsandra gallina
 director-general</p></section></body></xml>